Castle Biosciences has achieved a significant milestone with its TissueCypher Barrett’s Esophagus test by delivering over 25,000 test reports since late 2021. This precision medicine test predicts the risk of progression from Barrett’s esophagus to esophageal cancer, which is crucial as Barrett’s esophagus is the only known precursor to esophageal adenocarcinoma, a rapidly increasing cancer in the U.S. with a low five-year survival rate. The TissueCypher test, supported by 14 peer-reviewed studies, surpasses traditional pathology diagnoses by providing personalized risk scores and actionable insights for clinicians.
The importance of this milestone lies in the potential to empower clinicians to make more informed decisions for their patients with Barrett’s esophagus, ultimately leading to the prevention of esophageal cancer diagnoses in the future. By determining an individual’s risk of progression to esophageal cancer, TissueCypher offers physicians an actionable risk score and personalized five-year risk assessment. This information can guide clinicians in adjusting surveillance intervals or recommending interventions to prevent unnecessary medical procedures for patients with a low-risk result or to prompt increased surveillance or intervention for those with a high-risk result.
This advancement in precision medicine marks a significant step forward in disease management, prioritizing the well-being of patients, clinicians, employees, and investors. Castle Biosciences’ commitment to improving health through innovative tests underscores the importance of personalized and risk-aligned insights in guiding patient care. The TissueCypher Barrett’s Esophagus test’s ability to provide tailored risk assessments and preventive strategies highlights the potential to transform the landscape of esophageal cancer management.
With ongoing research and development efforts in various diseases, including skin cancers, mental health conditions, and uveal melanoma, Castle Biosciences continues to lead the way in diagnostic advancements. Through tests like TissueCypher, the company aims to revolutionize disease management and improve patient outcomes. By staying at the forefront of precision medicine, Castle Biosciences sets a standard for innovative and patient-centered care in the healthcare industry.
